Wednesday, October 28, 2026

Fortinet (NASDAQ: FTNT) - Do Nothing - Q3 FY12/26 Earnings Review

Fortinet’s revenue rose 20% to $2.08 billion, but its 15% Q4 growth guide drove a 25% post-earnings stock drop as product, billings and services growth decelerated.

FTNT $94B

Cestrian Capital Research Oct 28 5 clicks

Oct 28 GOOGL $3.4T

Google Q3 FY12/26 Earnings Review

Cestrian Capital Research 2 clicks

Oct 28 MSFT $4T

MSFT Q1 FY6/27 Earnings Review

Cestrian Capital Research 1 click

From X

@AsifSuria Aug 19

Asif Suria on X

We track insider buying in spinoff or their parents in a custom screen on InsideArbitrage that we like to call the Spinsider. There were three companies (spinoffs or parents of spinoffs) that saw insider buying based on Form 4s filed recently. 1. The home safety and security solutions provider Resideo $RESI completed the spinoff of ADI Global Distribution $ADGI just two weeks ago. This week we saw three different insiders of $RESI buy stock on the open market including the CEO and the General Counsel. $RESI was spun out of Honeywell $HON in 2018, making $ADGI Honeywell's grandchild. 2. Enviri $NVRI was less of a spinoff and more of a breakup. It sold its Clean Earth division to to Veolia Environnement S.A. and paid out $15 per share to shareholders from the proceeds of the sale. It then spun out its Harsco Environmental and Rail divisions and renamed them as Enviri just to confuse us a little. This new Enviri saw insider buying by two insiders including the CEO this week. @valuedontlie especially likes these "stubs" as he likes to call them and has done well with stubs like Starz Entertainment $STRZ Much to my detriment, I kept Lions Gate Studios $LION after the spinoff and sold Starz. 3. The building materials company Amrize $AMRZ, which was spun out of Holcim AG in June 2025 continues to see significant insider buying activity. This month six different insiders including the CFO and the Chief Strategy & M&A Officer purchased shares.

@blondesnmoney Aug 19

Cluseau Investments on X

If you buy the $SNDK Dec 2028 1560 Straddle the stock would have to drop below $30 to make money on the downside

@BlueDuckCap Aug 19 1 click

BDC on X

Could happen. Also - there will be a massive 2ndary soon and insiders will start dumping shares. I wish this was a cure for cancer. It is not. If it ever even commercializes (still a big if) it will be just another thearaputic that will be sold along with Keytruda and in some cases may deter relapse. That's it. In fact, we may learn that the same lipid nano particles that the mrna technology relies on and which have been speculated to be a cancer causer in their own right (hint, they are) actually cause occurence of other cancers such as colon and pancreatic and breast. Does lowering recurrence in melanoma in exchange for a higher chance of colon cancer sound like a "cure"? I wish it was. No material position as of now. Congrats to bulls, I guess. $MRNA

@pernasresearch Aug 19

Pernas Research on X

I forget who tweeted this about a year ago, but they used $NKE as a great example of a low-volatility, blue-chip stock that was risky. They deserve credit. Low volatility and blue chip do not mean low risk. https://t.co/RhNJPBUlJM

@kab604 Aug 19

kab60 on X

$JKHY: "We delivered a record 58 competitive core wins for the year, including 14 institutions with more than $1B in assets, and both fourth-quarter and full-year non-GAAP revenue reached new highs." WONDER WHO THEY WON THOSE FROM $FISV https://t.co/60Z4Tv8OCK

@stockgutter Aug 19 1 click

SG on X

$MRNA news could be a huge breakthrough (probably will take years to know one way or the other), or it could be something not replicated in other trials. Either way the move is just enormous and the likelihood of a raise in the next few months is very high imo. Selling a few Jan27 220 calls, priced around 22.

@kab604 Aug 19

kab60 on X

The way mkt values $FIS vs $JKHY is as if it's $AAP vs. $ORLY / $AZO. Wait to see what happens when mkt realizes it's a StiCKY, mIsSiOn CriTiCaL sYStEm oF reCoRD cOmPounDiNG FCF/SHARE > 15%!!! #NEVERSELL

@evantindell Aug 19 1 click

Evan Tindell on X

Hi please bring me all of your most bearish arguments on $MRNA and why this price is unsustainable, the final phase 3 data won't be that good, it won't work in other cancers, etc

Microsoft Corp Earnings Update: Fiscal Q1 2027

Microsoft’s fiscal Q1 revenue rose 19% as Azure grew 48%, while $45.2 billion of capex including finance leases cut free cash flow 27%;…

MSFT $4T

SixSigmaCapital: Navigating the Financial Markets Oct 28 2 clicks

Culper Research vs Cerebras: A Neutral Engineering-Driven View

Cerebras’ alleged electromigration issues hinge on temperature and voltage limits, not total power draw, while thermal variation and…

CBRS $24B

Irrational Analysis Oct 28 3 clicks

CoStar 3Q26 Recap: Cost Decreases Cost of Growth

CoStar’s 14% revenue growth, $37 million in net new bookings and 14% stock drop sharpen doubts that sales and marketing cuts can coexist…

CSGP $13B

Speedwell Research Oct 28 1 click

Group 1 Automotive (GPI): Q3 2026 Earnings

Group 1 Automotive trades at 5.5 times earnings as aging gasoline vehicles and EV repairs sustain service profits; insiders bought while…

TSLA $1.5TPAG $14B

Cannibal Stocks Oct 28 1 click

Cerebras ($CBRS): A Neocloud Masquerading as a Chipmaker

Cerebras relies on OpenAI for almost all of its $25 billion backlog while renting AI capacity, raising questions over its semiconductor…

CBRS $24B

Shallow Dives Oct 28 4 clicks

Danaher’s robotics era

Danaher’s new CEO paired a Q3 beat and raised EPS outlook with a 2027 4%-5% organic-growth starting point, while pitching AI-enabled…

DHR $165B

Best Anchor Stocks Oct 28 1 click

The Cigna Group: Client Retention Matters, But Contract Profitability Matters More

Cigna faces PBM margin pressure as employer fee demands and Signature transition costs outweigh specialty-drug growth, limiting profit…

CI $80B

Narek Hovhannisyan Oct 28 1 click

SWI #25 & #26 - Monopoly in Hybrid Bonding (BESI), Monopoly in Lithography (ASML)

Besi and ASML dominate hybrid bonding and lithography equipment, positioning both European semiconductor suppliers for AI-driven chip…

ASML $575B

Sleep Well Investments Oct 28 7 clicks

Alibaba: At $100, The Market Is Pricing The Bear Case

Alibaba's $100 valuation discounts cloud growth, China competition and US investment-ban risk, while its cloud unit posted 45% revenue…

BABA $262B

M&M Capital Oct 28 2 clicks

Meta Earnings, Muse and the Frontier, Musebook

Meta’s earnings hinge on whether investors back Zuckerberg’s Muse vision and the compute spending required to build it.

META $1.6T

Stratechery by Ben Thompson – On the business, strategy, and impact of technology. Oct 27 1 click

ORCL Update

Oracle rose about 12% intraday on October 28, 2026 as AI infrastructure and cloud-demand sentiment improved and credit-spread concerns…

ORCL $383B

Cestrian Capital Research Oct 28 2 clicks

Vertiv (NYSE: VRT) Stock Rating: Accumulate, $329 Price Target After Q3 FY12/26 Earnings

Vertiv beat Q3 revenue guidance by $460 million, grew organic sales 55%, and raised full-year revenue guidance by $650 million to a $14.65…

VRT $79B

Cestrian Capital Research Oct 28 3 clicks

Seagate Q1: Earnings Beat, Stock Plunges But Valuation Concerns Exist (Rating Downgrade)

Seagate’s Q1 revenue rose 61% and adjusted EPS nearly tripled, but a 130% YTD rally leaves STX exposed if cyclical margins normalize.

STX $139B

Agar Capital Oct 27

EQT Q3 FY12/26 Earnings Review - Distribute Rating

EQT moved to Distribute at $56.29 after Q3 revenue fell 9.6%; a 44% trailing free-cash-flow margin signals cycle risk despite lower debt…

EQT $33B

Cestrian Capital Research Oct 27 2 clicks

Apple’s iPhone Duo in the flesh

Apple unveiled the iPhone Duo, its first foldable iPhone, at its Fifth Avenue Manhattan store.

AAPL $4.8T

The Technology Letter Oct 27 6 clicks

Anthropic Deep Dive

Anthropic’s $80.7 billion first-half loss was mostly fair-value marks, while $16.3 billion revenue and compute economics showed a $974…

AMZN $2.9T

CV's Substack Oct 27 7 clicks

My Last GFL Update - Hopefully

GFL’s take-private structure hinges on BC Partners rolling 60% of its stake to preserve debt portability under the 40% permitted-holder…

GFL $20B

310 Value’s Newsletter Oct 27 5 clicks

Expert Call | Lumentum Optical Chip Capacity, EML/SiPh Outlook & Industry Pricing

Lumentum’s 2027 optical-chip expansion, 200G EML and CW capacity, silicon-photonics roadmap, pricing and 3.2T module prospects face…

LITE $62B

P Equity Research Oct 27 2 clicks

Right-Sizing Memory

Micron’s AI memory demand depends on workload-specific accelerator designs that shift bits among HBM, GDDR and LPDDR, changing wafer…

MU $743BNVDA $5T

Chipstrat Oct 27 4 clicks

Are Neoclouds Dead?

Neoclouds face tighter debt financing as AI infrastructure capex outruns cash flow, leaving cash-burning GPU providers more exposed than…

NBIS $38B

Daniel Romero Oct 27 9 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

YouTube 4

Blogs 15

Seeking Alpha 73 of 273

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Nominate an account

Investor letters we follow

338 firms

Sectors

Ordered by how often our editor reaches for them.

Wednesday, October 28, 2026

Asif Suria on X

Cluseau Investments on X

BDC on X

Pernas Research on X

kab60 on X

SG on X

kab60 on X

Evan Tindell on X

Investor Letters

Publications we follow

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 73 of 273

X accounts we follow

Investor letters we follow

Sectors